Myosin VIIa Antibody

Product Discontinued

Myosin VIIa Antibody Summary

• Immunogen: This antibody was developed against Recombinant Protein corresponding to amino acids: WAVLTVQAYARGMIARRLHQRLRAEYLWRLEAEKMRLAEEEKLRKEMSAKKAKEEAERKHQERLAQLAREDAERELKEKEAARRKKELLEQMERARHEPVNHSDMVDKMFGFLGTSGGLPGQEGQAPSGFE
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: MYO7A
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1 - 4 ug/ml
  • Immunohistochemistry 1:200 - 1:500
  • Immunohistochemistry-Paraffin 1:200 - 1:500
• Application Notes: ICC/IF reported in scientific literature (PMID: 25760435). For IHC-Paraffin, HIER pH 6 retrieval is recommended. ICC/IF Fixation Permeabilization: Use PFA/Triton X-100.

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 28241887). Guinea Pig reactivity reported in the literature (PMID: 29945803)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2) and 40% Glycerol
• Preservative: 0.02% Sodium Azide
• Purity: Immunogen affinity purified

Alternate Names for Myosin VIIa Antibody

• deafness, autosomal dominant 11
• deafness, autosomal recessive 2
• DFNA11
• DFNB2
• myosin VIIA
• myosin-VIIa
• MYOVIIA
• MYU7A
• USH1Bsevere))

Background

Myosin VIIa is a member of the myosin superfamily of actin-based motor proteins. Defects in the myosin VIIa gene are responsible for hearing impairment in shaker-1 (sh1) mice and causes Usher syndrome IB in humans. Usher syndrome associates congenital deafness, vestibular dysfunction, and retinitis pigmentosa and is the most common form of combined deafness and blindness. Structural features of myosin VIIa protein include an ATP binding N-terminal motor domain, a central region which possess five light-chain binding (IQ) motifs, and a C-terminal domain with three myosin tail homology (MyTH4) and talin-like homology regions.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Myosin VIIa Antibody (NBP1-84266)(6)

Publications using NBP1-84266

• van Beelen ESA, van der Valk WH, Verhagen TO et al. Efficient Viral Transduction in Fetal and Adult Human Inner Ear Explants with AAV9-PHP.B Vectors Biomolecules 2022-06-10 [PMID: 35740941] (IF/IHC, Human)
• Hu L, Nomura S, Sato Y et al. Anti-inflammatory effects of differential molecular weight Hyaluronic acids on UVB-induced calprotectin-mediated keratinocyte inflammation Journal of dermatological science 2022-06-09 [PMID: 35717315] (IF/IHC, Human)
• Chen H, Liang C, Wang C et al. Transplantation of human limbus-derived mesenchymal stromal cells via occipital approach improves hearing in animal auditory neuropathy. Flow Cytometry Basics for the Non-Expert. 2018-11-09 [PMID: 30579092] (IF/IHC, Mouse)
• Schulze J, Sasse S, Prenzler N et al. Microenvironmental support for cell delivery to the inner ear Hear. Res. 2018-06-21 [PMID: 29945803] (ICC/IF, Guinea Pig)
• Mellott AJ, Shinogle HE, Nelson-Brantley JG et al. Exploiting decellularized cochleae as scaffolds for inner ear tissue engineering. Stem Cell Res Ther. 2017-02-28 [PMID: 28241887] (IF/IHC, Mouse)
• Mellott AJ, Devarajan K, Shinogle H et al. Non-viral reprogramming of human Wharton's jelly cells reveals differences between ATOH1 homologues. Tissue Eng Part A. 2015-03-11 [PMID: 25760435] (ICC/IF, Human)

Bioinformatics

• Gene Symbol: MYO7A